STELARA® safety and side effects data in adult patients with moderately to severely active UC

STELARA®: SAFETY PROFILE IN UC

The overall safety profile of STELARA® in UC was consistent with that seen in other approved indications1

The safety of STELARA® was evaluated in 2 randomized, double-blind, placebo-controlled clinical studies in 960 adult patients with moderately to severely active UC.

COMMON ADVERSE REACTIONS THROUGH WEEK 8 IN SINGLE IV INDUCTION STUDY1,2

≥3% of patients treated with STELARA® and higher than placebo STELARA®
6 mg/kg IV single dose (n=320)
Placebo(n=319)
Nasopharyngitis 7% 4%

COMMON ADVERSE REACTIONS THROUGH WEEK 44 IN SINGLE SUBQ MAINTENANCE STUDY1,2*

≥3% of patients treated with STELARA® and higher than placebo STELARA® 90 mg
subQ every 8 weeks(n=176)
Placebo (STELARA® IV Induction Responders randomized to placebo)(n=175)
Nasopharyngitis 24% 20%
Headache 10% 4%
Abdominal pain 7% 3%
Influenza 6% 5%
Fever 5% 4%
Diarrhea 4% 1%
Sinusitis 4% 1%
Fatigue 4% 2%
Nausea 3% 2%

Adverse Events THROUGH 1 Year1,2

  STELARA® 90 mg
subQ every 8 weeks
Placebo
N (treated patients) 176 175
Average duration of follow-up (weeks) 42.2 42.3
Deaths 0 0
Percentage of Patients
Adverse events 77.3% 78.9%
Serious adverse events 8.5% 9.7%
Infections 48.9% 46.3%
Serious infections 1.7% 2.3%

ADDITIONAL SAFETY AT 1 YEAR

<1% Hypersensitivity reactions1

No cases of anaphylactic or delayed hypersensitivity reactions with STELARA® through 1 year in the UC trials. <1% of patients taking STELARA® in the CD trials experienced hypersensitivity reactions.

<1% Malignancy rate

  • Nonmelanoma skin cancer: STELARA®: 0.4%; Placebo: 0.0%
  • Other malignancies: STELARA®: 0.5%; Placebo: 0.2%

STELARA® is an immunosuppressant and may increase the risk of malignancy.

<2% Serious infections2

1.7% of patients in the STELARA® 90 mg subQ every-8-weeks group reported serious infections vs 2.3% in the placebo group during the Phase 3 Maintenance Study.

<5% of patients developed antibodies1,2

4.6% of overall population treated with STELARA® and 3.4% of randomized patients treated with STELARA® 90 mg subQ every 8 weeks developed antibodies to the drug.

Antidrug antibodies can bind to therapeutic protein products, thereby reducing or inhibiting their efficacy3

The limited number of patients positive for antibodies to STELARA® limits the ability to draw definitive conclusions regarding the relationship between antibodies to STELARA® and clinical efficacy and safety measures. The data above reflect the percentage of patients whose test results were positive for antibodies to STELARA® at any visit in the UC clinical program and are highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody positivity in an assay may be influenced by several factors, including sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to STELARA® with the incidence of antibodies to other products may be misleading.

STELARA® safety in UC at 2 years

Adverse Events in The Open-label Lte Study through 2 Years2

  Patients treated with STELARA® 90 mg subQ every 8 weeks during open-label LTE Placebo
N (randomized and nonrandomized patients who entered the open-label LTE) 353 188
Average duration of follow-up (weeks) 77.7 81.3
Deaths 1|| 0
Percentage of Patients
Adverse events 81.3% 83.0%
Serious adverse events 7.9% 11.2%
Infections 56.7% 56.4%
Serious infections 2.5% 3.2%

ADDITIONAL SAFETY DURING OPEN-LABEL LTE (WEEK 0 OF MAINTENANCE STUDY TO WEEK 96)2

<1% Malignancy rate

  • STELARA® 90 mg every 8 weeks: 0.6% (2/353)
  • Placebo: 1.1% (2/188)

<3% Serious infections

  • STELARA® 90 mg every 8 weeks: 2.5% (9/353)
  • Placebo: 3.2% (6/188)

View safety profile of STELARA® in CD

CD=Crohn's disease; IV=intravenous; LTE=long-term extension; subQ=subcutaneous; UC=ulcerative colitis.

 

*Week 44 in the Maintenance Study was equivalent to 1 year after induction dose.

†Patients who were in clinical response to the STELARA® IV induction dosing and were randomized to placebo subQ on entry into this Maintenance Study.

‡Randomized patients in the Maintenance Study.

§Malignancy rates included here reflect a combined evaluation of patients treated with STELARA® including those randomized to either the q8w or q12w dosing regimen.

||After a prolonged hospitalization for a lumbar compression fracture secondary to osteoporosis and worsening of UC, a 73-year-old patient was transferred to a nursing facility for rehabilitation, where the patient ultimately died due to cardiac arrest.

References: 1. STELARA® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. 2. Data on file. Janssen Biotech, Inc. 3. Food and Drug Administration. Guidance for Industry: lmmunogenicity Assessment for Therapeutic Protein Products. Silver Spring, MD: Food and Drug Administration, US Department of Health and Human Services; 2014. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/immunogenicity-assessment-therapeutic-protein-products. Accessed October 2, 2019.